专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20100086946A1 PLGF, FLT1 AND ENDOGLIN FOR DIAGNOSING ANGIOGENIC STATUS IN CORONARY ARTERY DISEASE 审中-公开
标题翻译： PLGF，FLT1和内皮素用于诊断冠状动脉疾病中的血管生成状态
公开(公告)号：US20100086946A1
公开(公告)日：2010-04-08
申请号：US12487126
申请日：2009-06-18
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N33/53
CPC分类号： G01N33/74 , G01N33/6872 , G01N2333/475 , G01N2333/515 , G01N2333/71
摘要： Described are methods for diagnosing the angiogenic status of a subject suffering from coronary heart disease comprising determining the amounts of placental growth factor or a variant thereof, endoglin or a variant thereof and soluble FLT1 or a variant thereof in a sample of a subject suffering from coronary heart disease and comparing the amounts determined with reference amounts, whereby the angiogenic status is diagnosed. Also disclosed are diagnostic devices and kits for carrying out the aforementioned methods
摘要翻译：描述了用于诊断患有冠心病的受试者的血管生成状态的方法，其包括在患有冠状动脉的受试者样品中测定胎盘生长因子或其变体，内皮糖蛋白或其变体和可溶性FLT1或其变体的量心脏病并比较用参考量确定的量，从而诊断血管生成状态。还公开了用于实施上述方法的诊断装置和试剂盒

12. 发明申请

US20100081164A1 BIOCHEMICAL MARKERS FOR ACUTE PULMONARY EMBOLISM 有权
标题翻译：急性肺栓塞生物化学标记物
公开(公告)号：US20100081164A1
公开(公告)日：2010-04-01
申请号：US12632026
申请日：2009-12-07
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： C12Q1/02
CPC分类号： G01N33/6893 , G01N33/74 , G01N2333/58 , G01N2800/12
摘要： The present invention relates to a method of differentiating between a singular and a multiple lung embolism in a subject suspected to suffer from acute lung embolism comprising determining the amount of NT-proBNP in a sample of a subject suspected to suffer from acute lung embolism and comparing the amount to a reference amount. Further, the present invention also relates to a method of differentiating between acute and chronic lung embolism in a subject comprising determining the amount of NT-proANP at a first and a second time point and comparing the determined amounts with each other. The present invention also encompasses devices and kits for carrying out the aforementioned methods.
摘要翻译：本发明涉及一种区分疑似患有急性肺栓塞的受试者的单肺和多肺栓塞的方法，包括确定怀疑患有急性肺栓塞的受试者样品中的NT-proBNP的量，并比较金额为参考金额。此外，本发明还涉及在受试者中区分急性和慢性肺栓塞的方法，其包括在第一和第二时间点确定NT-proANP的量并将确定的量彼此进行比较。本发明还包括用于实施上述方法的装置和试剂盒。

13. 发明授权

US09983213B2 Identification of subjects being susceptible to anti-angiogenesis therapy 有权
公开(公告)号：US09983213B2
公开(公告)日：2018-05-29
申请号：US13010183
申请日：2011-01-20
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N33/53 , A61P35/00 , G01N33/68 , C07K16/18 , C07K14/47 , C07K14/475 , C07K14/515 , C07K16/22
CPC分类号： G01N33/6887 , A61P35/00 , C07K14/47 , C07K14/475 , C07K16/18 , C07K16/22 , G01N33/53 , G01N2333/4712 , G01N2333/58 , G01N2800/32 , G01N2800/52
摘要： The present invention relates to a method for identifying a subject being susceptible to anti-angiogenesis therapy based in determining the amount of a cardiac troponin in a sample of the subject and comparing the amount to a suitable reference amount. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.

14. 发明授权

US08501155B2 Biochemical markers for acute pulmonary embolism 有权
公开(公告)号：US08501155B2
公开(公告)日：2013-08-06
申请号：US12631926
申请日：2009-12-07
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： A61K49/00
CPC分类号： G01N33/6893 , G01N33/74 , G01N2333/58 , G01N2800/12
摘要： The present invention relates to a method of differentiating between a singular and a multiple lung embolism in a subject suspected to suffer from acute lung embolism comprising determining the amount of NT-proBNP in a sample of a subject suspected to suffer from acute lung embolism and comparing the amount to a reference amount. Further, the present invention also relates to a method of differentiating between acute and chronic lung embolism in a subject comprising determining the amount of NT-proANP at a first and a second time point and comparing the determined amounts with each other. The present invention also encompasses devices and kits for carrying out the aforementioned methods.

15. 发明授权

US08440463B2 Predicting renal failure in diabetes patients based on placental growth factor and soluble FLT-1 失效
标题翻译：基于胎盘生长因子和可溶性FLT-1预测糖尿病患者的肾功能衰竭
公开(公告)号：US08440463B2
公开(公告)日：2013-05-14
申请号：US12909140
申请日：2010-10-21
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N33/573
CPC分类号： G01N33/689 , G01N33/6863 , G01N33/74 , G01N2333/475 , G01N2333/515 , G01N2333/71 , G01N2800/042 , G01N2800/347
摘要： Disclosed is a method for predicting the risk of developing renal failure or mortality for a subject suffering from diabetes mellitus. More specifically, a method is disclosed for predicting the risk of developing renal failure for a subject suffering from diabetes mellitus, the method including the steps of determining the amounts of PLGF and sFlt-1 in a sample of a subject suffering from diabetes mellitus and comparing the amounts of PLGF and sFlt-1 determined with reference amounts of PLGF and sFlt-1, whereby the risk of developing renal failure is predicted. Also disclosed are diagnostic devices and kits for carrying out the aforementioned methods.
摘要翻译：公开了一种预测患有糖尿病患者的肾功能衰竭或死亡风险的方法。更具体地，公开了一种用于预测患有糖尿病的受试者发生肾衰竭的风险的方法，所述方法包括以下步骤：测定患有糖尿病的受试者的样品中的PLGF和sFlt-1的量，并比较用参考量的PLGF和sFlt-1测定的PLGF和sFlt-1的量，从而预测发生肾衰竭的风险。还公开了用于实施上述方法的诊断装置和试剂盒。

16. 发明授权

US08361800B2 Diagnostic means and methods using troponin T and NT-proBNP 有权
标题翻译：使用肌钙蛋白T和NT-proBNP的诊断手段和方法
公开(公告)号：US08361800B2
公开(公告)日：2013-01-29
申请号：US12465825
申请日：2009-05-14
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N33/00
CPC分类号： G01N33/6887 , G01N2333/4712 , G01N2333/58 , G01N2800/32 , G01N2800/325 , G01N2800/52
摘要： The present invention relates to diagnostic means and methods. Specifically, the present invention encompasses a method of diagnosing the cause of cardiac necrosis in a subject comprising determining the amount of a cardiac troponin and the amount of a BNP-type peptide in a sample from a subject suffering from cardiac necrosis and comparing the amount of the cardiac troponin and the amount of the BNP-type peptide to reference amounts, whereby the cause of the cardiac necrosis is to be diagnosed. The present invention further relates to a method of determining whether a subject suffering from cardiac necrosis is susceptible for a therapy against initial heart failure and to a method for determining whether a subject suffering from cardiac necrosis is susceptible for a therapy against coronary heart disease. Also encompassed are diagnostic uses, devices, and kits.
摘要翻译：本发明涉及诊断手段和方法。具体地，本发明包括诊断受试者心脏坏死原因的方法，包括确定来自患有心脏坏死的受试者的样品中心肌肌钙蛋白的量和BNP型肽的量，并比较心肌肌钙蛋白和BNP型肽的参考量的量，从而诊断出心脏坏死的原因。本发明还涉及确定患有心脏坏死的受试者是否易于针对初始心力衰竭的治疗的方法以及用于确定患有心脏坏死的受试者是否易于对冠心病的治疗的方法。还包括诊断用途，设备和工具包。

17. 发明申请

US20120252035A1 GDF-15 and/or Troponin T for Predicting Kidney Failure in Heart Surgery Patients 审中-公开
标题翻译： GDF-15和/或肌钙蛋白T预测心脏手术患者的肾衰竭
公开(公告)号：US20120252035A1
公开(公告)日：2012-10-04
申请号：US13525330
申请日：2012-06-17
申请人： Andrea Horsch , Dietmar Zdunek , Georg Hess
发明人： Andrea Horsch , Dietmar Zdunek , Georg Hess
IPC分类号： G01N21/76
CPC分类号： G01N33/74 , C07K14/4716 , G01N33/6863 , G01N33/6893 , G01N2333/4712 , G01N2333/495 , G01N2333/52 , G01N2800/347 , G01N2800/50 , G01N2800/52
摘要： The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and/or a natriuretic peptide.
摘要翻译：本公开涉及实验室诊断领域。具体地，公开了用于基于检测GDF-15，肌钙蛋白T和/或利尿钠肽来确定在外科手术后患有急性肾损伤的患者的风险的手段和方法。

18. 发明申请

US20120214180A1 NT-pro ANP and SFlt-1 FOR THE DIFFERENTIATION BETWEEN CIRCULATORY AND ISCHEMIC EVENTS 有权
标题翻译： NT-pro ANP和SFlt-1用于循环和分离事件之间的差异
公开(公告)号：US20120214180A1
公开(公告)日：2012-08-23
申请号：US13461833
申请日：2012-05-02
申请人： Georg Hess , Dietmar Zdunek , Andrea Horsch
发明人： Georg Hess , Dietmar Zdunek , Andrea Horsch
IPC分类号： G01N33/566
CPC分类号： G01N33/6893 , G01N2333/58 , G01N2333/71 , G01N2800/32 , G01N2800/347
摘要： The present disclosure relates to the field of laboratory diagnostics. The present disclosure provides means and methods for differentiating between an acute circulatory event and an ischemic event, as the cause underlying an acute medical event of a patient.
摘要翻译：本公开涉及实验室诊断领域。本公开提供了用于区分急性循环事件和缺血事件的手段和方法，作为患者急性医疗事件的原因。

19. 发明申请

US20120164669A1 MARKER PANEL FOR LEFT VENTRICULAR HYPERTROPHY 审中-公开
标题翻译：用于左心室超声的标记面板
公开(公告)号：US20120164669A1
公开(公告)日：2012-06-28
申请号：US13416579
申请日：2012-03-09
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N21/76
CPC分类号： G01N33/6893 , G01N2333/4712 , G01N2333/475 , G01N2333/58 , G01N2800/325 , G01N2800/52
摘要： The present disclosure relates to methods, compositions, kits and devices for diagnosing, distinguishing and/or facilitating a therapeutic decision in a subject having left ventricular hypertrophy. In some aspects, the methods, compositions, kits and devices disclosed herein allow for diagnosing, distinguishing and/or facilitating a therapeutic decision in a subject having physiological left ventricular hypertrophy, and/or for a subject suffering from pathological left ventricular hypertrophy.
摘要翻译：本公开涉及用于诊断，区分和/或促进具有左心室肥大的受试者的治疗决定的方法，组合物，试剂盒和装置。在一些方面，本文公开的方法，组合物，试剂盒和装置允许诊断，区分和/或促进具有生理性左心室肥大的受试者和/或患有病理性左心室肥大的受试者的治疗决定。

20. 发明申请

US20110159600A1 NATRIURETIC PEPTIDES AND ADIPONECTIN IN SUBJECTS WITH A METABOLIC SYNDROME 审中-公开
标题翻译：具有代谢综合征的受试者的NATRIURETIC PEPTIDES和ADIPONECTIN
公开(公告)号：US20110159600A1
公开(公告)日：2011-06-30
申请号：US13041519
申请日：2011-03-07
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N33/50 , B01J19/00
CPC分类号： G01N33/6893 , G01N2333/4703 , G01N2800/04 , G01N2800/50 , G01N2800/52
摘要： The present invention is concerned with a method for predicting the risk of mortality and/or a cardiovascular event in a subject who suffers from the metabolic syndrome based on the determination of a natriuretic peptide and adiponectin in a sample of a subject. Moreover, the present invention relates to a method for identifying a subject being susceptible to a therapy that intends to increase the level of adiponectin in a subject based on the determination of the aforementioned markers. Further disclosed are kits and devices adapted to carry out the method of the present invention.
摘要翻译：本发明涉及一种用于预测受试者患有代谢综合征的受试者的死亡风险和/或心血管事件风险的方法，其基于受试者样品中利尿钠肽和脂连蛋白的测定。此外，本发明涉及一种基于上述标记物的测定来鉴定易于进行治疗的受试者对增加受试者的脂联素水平的方法。还公开了适于实施本发明的方法的套件和装置。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式